IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Evidence

Opioid use disorder

LAST REVIEWED 2026-05-18 · 346 SOURCES · 0 CORRECTIONS

Observational detoxification reports, follow-up studies, and registered oral Ibogaine withdrawal research.

Confidence: ModerateSource type: Study
Evidence level
early human and observational
Sample sizes
Published studies and registries vary from small cohorts to planned early-phase trial stages; each source needs its own denominator.
Design quality
Often uncontrolled, selection-biased, and setting-dependent; approved medications remain the essential comparator.
Outcomes
Withdrawal interruption, craving, relapse, retention, adverse events, and functional recovery require separate measurement.
Limitations
Durability, relapse denominator data, missing follow-up, concurrent supports, and adverse-event denominator data remain incomplete.
Safety signals
Cardiac risk, concurrent substances, withdrawal physiology, electrolyte issues, psychiatric status, and medication interactions.
What is not proven
Ibogaine is not proven to cure opioid addiction.
Best next source
ClinicalTrials.gov NCT05029401 and peer-reviewed OUD detoxification outcome papers.